Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A preclinical study on the influence of linkers in [68Ga]Ga-NOTA-X-RM26 radiotracers for PET imaging of GRPR expression
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Preparative Medicinal Chemistry.ORCID iD: 0009-0008-6737-0336
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Theranostics. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.ORCID iD: 0000-0003-0209-2116
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Theranostics.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry.
Show others and affiliations
2025 (English)In: EJNMMI Research, E-ISSN 2191-219X, Vol. 15, no 1, article id 104Article in journal (Refereed) Published
Abstract [en]

Background

Gastrin-releasing peptide receptor (GRPR) is overexpressed in several cancers, including prostate and breast, making it an attractive target for radiopharmaceutical development. Studies on GRPR-targeting radioligands highlight the critical role of the spacer region between the GRPR-recognition motif and radiolabeled moiety, which can significantly influence peptide pharmacokinetics and pharmacodynamics. Herein, we investigated the impact of structurally restricted spacers on the performance of RM26-based radioligands.

Results

Three novel radioligands were designed to each bear a NOTA chelator via different spacers composed of N-acetyl-lysine followed by either o-ethyltoluene (oET), o-methylanisole (oMA), or m-methylanisole (mMA) motifs. The peptides were successfully labeled with Ga-68, achieving high radiochemical yield, purity, and molar activity. The resulting [68Ga]-labeled peptides demonstrated high and GRPR-specific binding to prostate cancer PC-3 cells, antagonistic behavior, and the IC50 values to GRPR were in the single-digit nanomolar range. Biodistribution studies at 2 h post-injection in PC-3 xenograft-bearing mice revealed high, GRPR-mediated tumor uptake for all three radioligands. In addition, high hepatobiliary excretion with elevated uptake in the liver and the gastrointestinal tract and pronounced pancreatic uptake were observed.

Conclusions

Among the three radioligands, the peptide bearing the N-acetyl-lysine-oET spacer exhibited the fastest background clearance and better PET imaging of prostate cancer xenografts. The incorporation of conformationally restricted spacers is a promising strategy for developing tracers with high GRPR binding and good imaging properties, but further optimization is necessary to reduce uptake in healthy tissues.

Place, publisher, year, edition, pages
Springer, 2025. Vol. 15, no 1, article id 104
Keywords [en]
Radiopharmaceuticals, GRPR, Bombesin analogue, Antagonist, Prostate cancer, Structure-properties relationship
National Category
Medicinal Chemistry Radiology and Medical Imaging Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-564152DOI: 10.1186/s13550-025-01301-yISI: 001545786000002PubMedID: 40775579Scopus ID: 2-s2.0-105012737092OAI: oai:DiVA.org:uu-564152DiVA, id: diva2:1985682
Part of project
Combined targeted radionuclide imaging and targeted therapy – a way for precision treatment of prostate cancer, Swedish Research CouncilSpatial Omics Enable Improved Pathophysiology-based Diagnosis of Parkinson´s Disease Dementia and Dementia with Lewy Bodies, Swedish Research CouncilNew and Enabling Chemical Tools for Molecular Imaging, Chemical Biology and Drug Discovery, Swedish Research Council
Note

De två första författarna delar förstaförfattarskapet

De två sista författarna delar sistaförfattarskapet

Authors in the list of papers of Esther Olaniran Håkansson's thesis: Olaniran Håkansson, E., Zelepukin, I.V., Obeid, K., Bitzios, A., Bezverkhniaia, E., Sunkara, A., Orlova, A., Odell, L.R., Kanellopoulos, P.

Available from: 2025-07-27 Created: 2025-07-27 Last updated: 2025-09-03Bibliographically approved
In thesis
1. Novel Synthetic Strategies for the Development of Peptides and Peptidomimetics in Alzheimer's Disease and Prostate Cancer
Open this publication in new window or tab >>Novel Synthetic Strategies for the Development of Peptides and Peptidomimetics in Alzheimer's Disease and Prostate Cancer
2025 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Peptides are attractive therapeutic agents due to their high target affinity and specificity. However, their clinical application is often limited by poor metabolic stability, rapid renal clearance and low bioavailability, necessitating chemical modifications to generate viable drug candidates. This thesis addresses these challenges through the development of safer synthetic methods and the design of modified peptides targeting two clinically relevant proteins: the insulin-regulated aminopeptidase (IRAP) in Alzheimer’s disease and the gastrin-releasing peptide receptor (GRPR) in prostate cancer. The first part focuses on method development for the safer generation of diazomethane, a key reagent in peptide modification, particularly for the synthesis of β3-amino acids via α-diazoketones in the Arndt-Eistert homologation. However, diazomethane is explosive and carcinogenic, limiting its practical use. In Paper I, we report a method for the in situ generation of diazomethane through a click and release reaction between an enamine and a sulfonyl azide, thereby eliminating the hazardous handling of diazomethane. This strategy enabled the synthesis of α-diazoketones and methyl esters of carboxylic acids under mild, base-free conditions. The second part investigates structure–activity relationships (SAR) of modified peptides targeting IRAP and GRPR. In Paper II, twelve novel analogues of the macrocyclic IRAP inhibitor HA08 were synthesised via a new divergent route focusing on C-terminal modifications. IRAP inhibition has shown cognitive benefits in preclinical models of Alzheimer’s disease. Thus, inhibitors like HA08 are potential cognitive enhancers. However, this peptidomimetic suffers from poor metabolic stability, necessitating further structural modifications. The SAR study revealed that aromaticity and correct spatial orientation at the C-terminus were crucial for IRAP inhibition. Papers III and IV focus on the development of GRPR antagonists for imaging and therapy in early-stage prostate cancer. GRPR is overexpressed in prostate tumour cells but minimally expressed in healthy tissues, making it a valuable molecular target for theranostic application. In Paper III, the influence of rigidity and lipophilicity of aromatic linkers in 68Ga-labelled radiopeptides for PET imaging was explored. Moderate lipophilicity improved tumour uptake and imaging contrast, suggesting that fine-tuning linker properties can optimise radioligand pharmacokinetics. Finally, therapeutic application of GRPR antagonists requires enhancement of circulatory half-life to prolong tumour irradiation. In paper IV, albumin-binding moieties (ABMs) were incorporated into 117Lu-labelled radiopeptides, which extended circulatory half-life for all conjugates and increased GRPR-mediated uptake. The position and lipophilicity of the ABM strongly influenced biodistribution profile of the radioconjugates, with [177Lu]Lu-CA6356 and [177Lu]Lu-CA6357 showing the most favourable profile. 

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2025. p. 117
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 380
Keywords
Peptides, peptidomimetics, insulin-regulated aminopeptidase (IRAP), inhibitor, neurodegenerative diseases, prostate cancer, gastrin-releasing peptide receptor (GRPR), radiopharmaceuticals, theranostics, PET imaging, Alzheimer’s Disease.
National Category
Medicinal Chemistry
Identifiers
urn:nbn:se:uu:diva-564154 (URN)978-91-513-2533-0 (ISBN)
Public defence
2025-09-12, B42, BMC, Husargatan 3, Uppsala, 13:15 (English)
Opponent
Supervisors
Available from: 2025-08-21 Created: 2025-07-28 Last updated: 2025-08-21

Open Access in DiVA

fulltext(2091 kB)511 downloads
File information
File name FULLTEXT01.pdfFile size 2091 kBChecksum SHA-512
f5baa84bba3eee8c350c753e5b50688a4e115332211ddc2e85bb8c9904afb9446562b2767970bf9b86bec8065d927ae973e7edf06cb5375e6e1d60ab39adb940
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Olaniran Håkansson, EstherZelepukin, Ivan V.Obeid, KarimBitzios, AthanasiosBezverkhniaia, EkaterinaRosenström, UlrikaOrlova, AnnaOdell, Luke R.Kanellopoulos, Panagiotis
By organisation
Preparative Medicinal ChemistryTheranosticsCancer precision medicineDepartment of Medicinal ChemistryScience for Life Laboratory, SciLifeLab
In the same journal
EJNMMI Research
Medicinal ChemistryRadiology and Medical ImagingCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 511 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 1040 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf